Supply Chain Council of European Union | Scceu.org
Supply Chain Risk

China’s quest for mRNA vaccine hits stumbling block in omicron

DALIAN, China — China continues to struggle in developing a homegrown mRNA vaccine against COVID-19, with its front-runner failing to reach the market by the end of last year as hoped and now showing disappointing results against the highly infectious omicron variant.

Related posts

Head-To-Head Contrast: Enstar Group (NASDAQ:ESGR) versus AXIS Capital (NYSE:AXS)

scceu

What will save China’s economy? Not Beijing’s 33-point stimulus plan

scceu

Q&A: Climate change and risks for future health crises

scceu